This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.

Things are certainly heating up in the pursuit of justice for the thousands of victims of Fosamax femur fracture injuries.

I am excited to announce that the first Fosamax femur fracture trial is currently set to begin in March of 2013 in Superior Court in Atlantic County, New Jersey.  A second Fosamax femur fracture trial is also set to begin in April of 2013 in the United States District Court for the District of New Jersey.

Importantly, the approach of these trial dates has also triggered some very significant discovery disclosure requirements. Merck, the manufacturer of Fosamax, was required by court order to disclose the identities of alleged expert witnesses it intends to call during upcoming femur fracture trials. It is a sad fact that many of these experts encompass the “usual suspects” of hired guns in the medical field that will testify to anything that Merck requires.

A little background on Fosamax femur fractures: From my perspective as a Fosamax femur fracture attorney, it is well-settled that research has confirmed an association between Fosamax and atypical femur fractures. Studies published in the New England Journal of Medicine, Journal of Bone and Mineral Research and the Journal of Orthopedic Trauma have all linked Fosamax to atypical femur fractures. Part of this is due to that fact that Fosamax is a drug with a long half-life, meaning it remains in the body even after use is discontinued. This means even women who didn’t take Fosamax for long may be susceptible to the atypical femur fractures this osteoporosis drug may cause.

Fosamax femur fractures may also develop because the drug is interfering with the bone remodeling process, resulting in the development of brittle bones. Fosamax hardens the outer layer of bone cells, preventing those cells from being replaced through normal bone remodeling. Consequently, tiny fractures can accumulate and result in Fosamax femur fractures.

Fosamax femur fractures are considered “low-energy,” meaning that the bone fractures result without serious trauma. Fosamax fractures have reportedly developed when the patient was walking, ascending steps or participating in a low-energy exercise. Fosamax leg fractures are said to be spontaneous in nature and atypical, as they develop in the long part of the thigh bone and the bone below the hip joint, which are not typically affected by osteoporotic fractures. In fact, the femur is one of the largest and strongest bones in the body.

The depositions of Merck’s expert witnesses will provide crucial information on how Merck intends on defending Fosamax femur fracture cases at a time of trial and are currently set to conclude by the end of January.

If you or a loved one was prescribed Fosamax and suffered a femur fracture, please contact The Michael Brady Lynch Firm for a no-cost, confidential evaluation of your case.

About the Firm: The Michael Brady Lynch Firm is a trial firm with a focus on pharmaceutical mass tort cases involving SSRI and Anti-Seizure Medication Birth Defects such as Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil, Depakote and Topamax, as well as Actos Bladder Cancer, Pradaxa bleeding and Fosamax Femur Fractures, and medical device cases including DePuy Hip and Trans-Vaginal Mesh cases. Contact us today if you or someone you know has experienced side effects involving these products.